-
Mashup Score: 0Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations - ILCN.org (ILCN/WCLC) - 1 year(s) ago
During TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients - ILCN.org (ILCN/WCLC) - 1 year(s) ago
Dr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #TTLC23, @LudaBazhenovaMD and @JustinGainor debated whether lorlatinib should be given to all ALK patients in the first line. Read a recap in #ILCN: https://t.co/dy84A54xeC #LCSM
-
-
Mashup Score: 1ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology - ILCN.org (ILCN/WCLC) - 1 year(s) ago
In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During the #TTLC23 faculty dinner, Dr. Corey J. Langer recounted perils, pitfalls, promises, and poetry from 35 years in thoracic oncology. Read a recap in #ILCN: https://t.co/06U7k0Ucc7 #LCSM
-
-
Mashup Score: 3Improved Understanding of Biomarkers in Tumor Microenvironment Key for Treatment Decisions in NSCLC - 1 year(s) ago
Brian S. Henick, MD, discusses the importance of expanding on the current knowledge of biomarkers and the tumor microenvironment to enhance treatment approaches for patients with non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Improved Understanding of Biomarkers in Tumor Microenvironment Key for Treatment Decisions in NSCLC @BHenickMD @columbiacancer @IASLC #TTLC23 #lcsm https://t.co/oOsvUSmV5m
-
-
Mashup Score: 2Scenes from TTLC 2023 - ILCN.org (ILCN/WCLC) - 1 year(s) ago
Revisit all your favorite moments from #TTLC23 in our photo gallery.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @TerriConneran: SOO much #fun making a difference in #lungcancer #TTLC23 @IASLC @KRASKickers https://t.co/bKG2jQgfUU
-
-
Mashup Score: 0Scenes from TTLC 2023 - ILCN.org (ILCN/WCLC) - 1 year(s) ago
Revisit all your favorite moments from #TTLC23 in our photo gallery.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Revisit your favorite moments from #TTLC23 in this photo gallery from #ILCN: https://t.co/LGJWWhxBzo #LCSM
-
-
Mashup Score: 3Targeted Therapies - Consolidated Radiation | IASLC - 1 year(s) ago
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation abou …
Source: IASLCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode, recorded at #TTLC23, @NarjustFlorezMD moderates a conversation about the use of consolidated radiation in early-stage #SCLC. Joining the debate are Dr. Lawrence Einhorn (@IUMedSchool) & Dr. Charles Simone (@MSKCancerCenter). Listen: https://t.co/ft0qWTCeuy #LCSM https://t.co/fHQPyFJMFE
-
-
Mashup Score: 4Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations - ILCN.org (ILCN/WCLC) - 1 year(s) ago
During TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #TTLC23, experts debated the pros and cons of continued TKI use with chemotherapy for EGFR-positive patients with disease progression. Read a recap in #ILCN: https://t.co/bvNZVrSbEV @DrSteveMartin #LCSM
-
-
Mashup Score: 1TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies - ILCN.org (ILCN/WCLC) - 1 year(s) ago
During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During #TTLC23, Keynote Speaker @LaurenByersMD celebrated recent progress in #SCLC research. Read a recap in #ILCN: https://t.co/Ktwc1tiZg4 #LCSM
-
-
Mashup Score: 0TTLC 2023 Meeting Recap | IASLC - 1 year(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests discuss the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23. TTLC …
Source: IASLCCategories: Hem/Oncs, Latest HeadlinesTweet-
Recap of #TTLC23 in the latest episode of #LungCancerConsidered, the official @IASLC podcast, with co-chairs Drs. @CharuAggarwalMD and @JoelNealMD as guests. Listen below! #LCSM https://t.co/FWwBOCVezL
-
During the Best Fellows Oral Abstract Session at #TTLC23, @HopkinsThoracic's Tia Cheunkarndee presented data on first-line osimertinib and uncommon EGFR mutations. Read a recap in #ILCN: https://t.co/3DT2mBk3Q8 #LCSM